Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1405&sort=-title
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-title", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-title", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1406&sort=-title", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1404&sort=-title" }, "data": [ { "type": "Grant", "id": "7495", "attributes": { "award_id": "3U01DA041048-06S1", "title": "8/21 ABCD-USA CONSORTIUM: RESEARCH PROJECT SITE AT CHLA", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 21593, "first_name": "Bethany", "last_name": "Deeds", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2015-09-30", "end_date": "2027-03-31", "award_amount": 180234, "principal_investigator": { "id": 23294, "first_name": "Megan Marie", "last_name": "Herting", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1555, "ror": "https://ror.org/00412ts95", "name": "Children's Hospital of Los Angeles", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23295, "first_name": "ELIZABETH R", "last_name": "SOWELL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1555, "ror": "https://ror.org/00412ts95", "name": "Children's Hospital of Los Angeles", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Adolescent Brain Cognitive Development (ABCD) study is the largest long-term study of child health and brain development in the US, consisting of a Coordinating Center, a Data Analysis and Informatics Resource Center, and 21 research sites. The ABCD Study has enrolled a diverse cohort of 11,878 9-10-year-olds and will continue to track their biological and behavioral development through adolescence into young adulthood. All participants receive neuroimaging, neuropsychological testing, bioassays, and detailed youth and parent assessments of substance use, mental health, physical health, and culture and environment. In March 2020, when our participants were ages 11-13, the world became substantially affected by the COVID-19 pandemic, leading to an upheaval in the economy and the lives of almost every family. Most U.S. schools closed to reduce viral spread. Many parents incurred changes in work (e.g., working-from-home, longer shifts, reduced wages, job loss). Some services and support systems became disrupted. And, the number of confirmed cases and deaths have continued to surge. The massive multifaceted impact of this unprecedented event has the potential to affect today’s children for decades to come. Here, we propose to leverage ABCD’s infrastructure, cohort, and existing protocol to rapidly characterize the impacts of the COVID-19 pandemic on each child in the study. In this proposal, we will capitalize on funded (NSF; PI Tapert) and pending supplements to administer queries to all ABCD participants and their parents about the impact of the pandemic on their lives (family level impact) by also incorporating publicly and privately available measures of community-level COVID-19 impacts. For participants’ neighborhoods (e.g., census tract, county, state), we will geocode measures of incidence, spatial distancing, changes in (un)employment, and timing of implementation of state and/or local policies on mitigation practices. By collecting this situational information at the family and community levels as soon as possible, we can use existing ABCD data to examine perturbations in developmental trajectories of brain functioning, cognition, substance use, academic achievement, social functioning, and physical and mental health. Specifically, we will (1) focus on characterizing the nature and variability of the community and regional impact of COVID-19, based on geocoding of ABCD participants’ neighborhoods (i.e., current home address) and (2) determine how community-level and family-level impacts of COVID-19 differentially influence stress, cognition, and mental health during and after the pandemic. We will analyze (1) the interactions between family- and community-specific impacts on ABCD participants’ immediate stress and mental health during the pandemic, (2) the extent to which such potential impacts are associated with each other, and (3) how both community and family factors (e.g., SES, neighborhood characteristics) may serve as protective factors. This unprecedented crisis provides an opportunity to exploit ABCD’s infrastructure and scientific rigor to discern critical dimensions of development not previously envisioned.", "keywords": [ "10 year old", "Academic achievement", "Acute", "Address", "Administrative Supplement", "Adolescence", "Adolescent", "Adolescent Development", "Adopted", "Affect", "Age", "Alcohol or Other Drugs use", "Area", "Behavioral", "Biological", "Biological Assay", "Brain", "COVID-19", "COVID-19 pandemic", "Cellular Phone", "Censuses", "Cessation of life", "Characteristics", "Child", "Child Health", "Chronic stress", "Cognition", "Collection", "Communities", "Coronavirus", "County", "Data", "Data Analyses", "Data Collection", "Development", "Dimensions", "Disasters", "Economics", "Employment", "Enrollment", "Environment", "Event", "Exposure to", "Family", "Funding", "Home environment", "Incidence", "Income", "Individual", "Infection", "Infrastructure", "Intervention", "Lead", "Link", "Longitudinal Studies", "Measurement", "Measures", "Mental Health", "Moods", "Movement", "National Institute of Drug Abuse", "Nature", "Neighborhoods", "Neuropsychological Tests", "Occupations", "Outcome", "Parents", "Participant", "Patient Self-Report", "Pattern", "Policies", "Population Density", "Prevalence", "Prevention", "Protocols documentation", "Questionnaires", "Reporting", "Research", "Research Project Grants", "Resource Informatics", "Risk", "Risk Factors", "Schools", "Services", "Shock", "Site", "Social Distance", "Social Functioning", "Socioeconomic Status", "Source", "Stress", "Structure", "Support System", "Unemployment", "United States", "Variant", "Viral", "Wages", "Work", "Youth", "base", "cognitive development", "cohort", "experience", "infrastructure development", "lower income families", "mortality", "neuroimaging", "pandemic disease", "payment", "physical conditioning", "protective factors", "resilience", "response", "young adult" ], "approved": true } }, { "type": "Grant", "id": "14713", "attributes": { "award_id": "1R13DK139767-01", "title": "7th International Enteric Nervous System Development Meeting: Connection, Cross-talk and Collaboration", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" ], "program_reference_codes": [], "program_officials": [ { "id": 12352, "first_name": "Terez", "last_name": "Shea-Donohue", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-03-07", "end_date": "2025-03-31", "award_amount": 14250, "principal_investigator": { "id": 31406, "first_name": "Allison Leigh", "last_name": "Speer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 788, "ror": "", "name": "UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "In the past several decades, researchers have made extraordinary progress in our understanding of enteric nervous system (ENS) development and function. Vital scientific advances have occurred in identifying the major signaling pathways, transcription control, migratory behavior, enteric neuronal and glial subtypes, microenvironmental factors, genetics, and neurotransmitter physiology require for normal ENS development. This exponential growth in scientific contributions to the field of ENS development has greatly enhanced our understanding of Hirschsprung's disease, the most common congenital enteric neuropathy, and has informed recent studies in the generation of neuronal stem/progenitor cells for cell-based regenerative medicine therapies to treat enteric neuropathies. The first international ENS development meeting occurred in New York in 2006, supported in part by a R13 grant from the NIH. This triennial meeting was subsequently held in London (2009), Hong Kong (2012), Rotterdam (2015), Boston (2018), and Ferrara (2022). The symposium is truly bench to bedside, bringing together bench researchers such as molecular and cellular biologists, geneticists, physiologists, and stem cell investigators and bedside clinicians such as gastroenterologists and surgeons, who all share a common interest in the development and function of the ENS and improving current management for enteric neuropathies. All of the ENS development meetings have been quite successful, with a growing number of attendees from 130 to nearly 200 in recent years from over 20 different countries in 5 continents from around the world. The 7th International Enteric Nervous System Development Meeting: Connection, Cross-talk and Collaboration will be held in Philadelphia in March 2024. This will be the first meeting focused on ENS development held in the U.S. since the COVID-19 pandemic and builds upon the success of prior meetings as well as the growing significance and relevance of ENS research. The specific aims of this R13 application are 1) to encourage and inspire the participation of young investigators, especially groups under-represented in science such as women, minorities, and socioeconomically disadvantaged individuals at this 7th International ENS Development Symposium by offering 20 Travel Awards to offset registration costs and travel expenses as well as 12 Scientific Merit Awards to highlight and promote accomplished young investigators; and 2) to improve the likelihood of long-term success for young investigators pursuing academic careers in the field of ENS development and function by establishing lasting mentored relationships with select faculty and members of the meeting’s International Organizing Committee. We anticipate that this unique ENS Development meeting will build meaningful mentorship and collaborations that will enhance the career development of the award recipients.", "keywords": [ "Award", "Behavior", "Boston", "COVID-19 pandemic", "Cells", "Cellular biology", "Clinical Management", "Collaborations", "Congenital Megacolon", "Constipation", "Country", "Data", "Development", "Discipline", "Disease", "Economically Deprived Population", "Enteral", "Enteric Nervous System", "Faculty", "Fostering", "Funding", "Future", "Gastroenterologist", "Generations", "Genetic", "Goals", "Grant", "Growth", "Hong Kong", "Image", "Individual", "Infant", "International", "K-Series Research Career Programs", "Knowledge", "London", "Manuscripts", "Mentors", "Mentorship", "Minority", "Molecular", "Molecular Biology", "Neural Crest", "Neurons", "Neurotransmitters", "New York", "Outcome", "Participant", "Pathologist", "Philadelphia", "Physicians", "Physiology", "Publishing", "Regenerative Medicine", "Research", "Research Personnel", "Science", "Scientific Advances and Accomplishments", "Scientist", "Signal Pathway", "Surgeon", "Systems Biology", "Systems Development", "Transcriptional Regulation", "Travel", "Underrepresented Populations", "United States National Institutes of Health", "Woman", "bench to bedside", "career", "cost", "enteric neuropathy", "improved", "interest", "meetings", "member", "nerve stem cell", "nervous system development", "public health relevance", "socioeconomic disadvantage", "stem cell biology", "stem cells", "success", "symposium", "synergism", "systems research" ], "approved": true } }, { "type": "Grant", "id": "6928", "attributes": { "award_id": "1R13HL163882-01", "title": "7th GenTAC Thoracic Aortic Disease Summit", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 10288, "first_name": "Patrice", "last_name": "Desvigne-Nickens", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-01", "end_date": "2023-03-31", "award_amount": 25447, "principal_investigator": { "id": 22772, "first_name": "Kim", "last_name": "Eagle", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22773, "first_name": "Marion A", "last_name": "Hofmann Bowman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "This application is in request for support for the 7th GenTAC Thoracic Aortic Disease Summit to be held in Paris, France on April 28, 2022. This unique meeting brings together multidisciplinary groups of clinicians, scientists, and engineers to advance our understanding of the underlying mechanisms of thoracic aortic disease and to improve our ability to treat those who are afflicted by these conditions, which includes both young and old. The 7th GenTAC summit for the first time will be held in collaboration 11th International Research Symposium on Marfan Syndrome (held April 24-27 at the same location) and is organized jointly with the Marfan Foundation. This shared meetings provides a forum not only where ideas are shared and scrutinized, but new collaborations are born. The biannual GenTAC conference originated in 2009 as part of the mission of the National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Related Cardiovascular Conditions (GenTAC). GenTAC was funded by NHLBI and NIAMS and enrolled and followed over 3600 patients from 2006 through 2016. Gentac Alliance was initiated in 2017 to harness the synergy and collaboration created by the GenTAC. The 5th GenTAC Summit was held on Oct 6-7, 2018 at OHSU in Portland, OR and the 6th GenTAC Summit was held virtually due to the covid-19 pandemic on October 10/11 2020. The preliminary program for this 1-day GenTAC summit includes scientific sessions on (i) Familial Aortopathy, (ii) Bicuspid aortic valve, (iii) Turner Syndrome, and (iv) Acute aortic syndrome. There will be synergy with the program of the 11th Research Symposium on Marfan syndrome. We anticipate that clinicians and researcher will attend both meetings representing different groups in the field of thoracic aortic aneurysms including Marfan Foundation, IRAD, Montalcino Aortic Consortium, BAVCON, EDS-PCORI, Turners, and European Vascular Network are participating. We have >80% of invited speakers are confirmed. Participation of trainees and underrepresented minorities is especially encouraged by awarding 10 travel awards. The meeting is hosted by Marfan Foundation and the Frankel Cardiovascular Center at the University of Michigan. The core conference organization committee includes Dr. Marion A Hofmann Bowman and Dr. Kim Eagle as the principal investigators of this grant, and Dr. Josephine Grima from the Marfan Foundation. This team also successfully organized the 2020 6th GenTAC meeting. Kim A. Eagle is the Director of the Frankel Cardiovascular Center at the University of Michigan and the chair of the NHLBI sponsored GenTAC Alliance and he served as the study chair of the GenTAC registry from 2006-2016. Dr. Marion A Hofmann Bowman is a Clinical Associate Professor and Executive Medical Director of the MiAorta program at the University of Michigan. Her expertise is in clinical-translational research related to thoracic aortic disease.", "keywords": [ "Acute", "Aortic Diseases", "Award", "Basic Science", "Belgium", "Blood Vessels", "COVID-19 pandemic", "Cardiovascular system", "Chest", "China", "Clinical", "Clinical Sciences", "Collaborations", "Communication", "Eagles", "Engineering", "Enrollment", "European", "Faculty", "Foundations", "Funding", "Germany", "Grant", "Heart", "International", "Italy", "Japan", "Location", "Marfan Syndrome", "Michigan", "Mission", "National Heart Lung and Blood Institute", "National Institute of Arthritis and Musculoskeletal and Skin Diseases", "Netherlands", "Paris France", "Participant", "Patient Care", "Patients", "Physician Executives", "Principal Investigator", "Registries", "Research", "Research Personnel", "Scientist", "Spain", "Structure", "Syndrome", "Thoracic Aortic Aneurysm", "Time", "Translational Research", "Travel", "Turner&apos", "s Syndrome", "Underrepresented Minority", "Universities", "Walking", "Woman", "bicuspid aortic valve", "career", "design", "experience", "improved", "lectures", "meetings", "mid-career faculty", "multidisciplinary", "novel", "posters", "programs", "social", "symposium", "synergism", "virtual" ], "approved": true } }, { "type": "Grant", "id": "6272", "attributes": { "award_id": "3R01CA202911-05S1", "title": "7T Neurosurgical Mapping Protocol for Endoscopic Resection of Skull Base Tumors", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 21206, "first_name": "DARAYASH B", "last_name": "TATA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-08-01", "end_date": "2021-03-31", "award_amount": 169495, "principal_investigator": { "id": 21207, "first_name": "Priti", "last_name": "Balchandani", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Although neurological symptoms are being observed in a high number of COVID-19 patients, a prospective study aimed at scanning recovered COVID-19 patients with advanced multi-modal neuroimaging methods has yet to be performed. There is much to be learned about the persisting effects of the SARS-CoV-2 virus on the central nervous system, and high-resolution magnetic resonance imaging (MRI) is the ideal non-invasive tool to reveal these effects as well as mechanisms of infection. In this work, we will leverage the high resolution and enhanced contrasts offered by multi-modal 7 Tesla (7T) imaging to study the structural, vascular, functional, and connectomic changes in the brain related to the pathophysiology of COVID-19. In particular, we will reveal, in unprecedented detail, brain abnormalities resulting from the SARS-CoV-2 infection as well as shine a brighter light on possible links to loss of respiratory drive due to viral infection through the brain stem. Imaging findings will be correlated to clinical neurological symptoms and neuropsychological measures. Three patient subgroups will be recruited for our prospective study: non-cancer patients with neurological symptoms who did not require a ventilator, cancer patients with neurological symptoms who did not require a ventilator, and patients who had severe respiratory distress and required ventilation. A retrospective study will also be performed on clinical brain MRI scans for a group of COVID-19 patients with neurological symptoms, seen at Mount Sinai Health System, and outcomes of this analysis will aid in patient selection for the 7T study and additional analysis of persisting versus transient neurological effects. Our study falls within the scope of our R01 application on “7T Neurosurgical Mapping Protocol for Endoscopic Resection of Skull Base Tumors” as we are applying similar multimodal 7T imaging techniques to reveal detailed anatomy in the brain and to characterize effects of disease in both studies. We will simply extend the cohort to include COVID-19 recovered patients and further optimize imaging in the brain stem which will be applicable to both studies. Our study aligns with the goals of the Notice of Special Interest announced by the NCI for administrative supplements on COVID-19 as it addresses potential for differential responses among diverse cancer patient populations to SARS-CoV-2 infection or COVID-19 disease in central nervous system.", "keywords": [ "2019-nCoV", "Address", "Administrative Supplement", "Adult Respiratory Distress Syndrome", "Age", "Anatomy", "Blood Vessels", "Brain", "Brain Injuries", "Brain Stem", "Brain region", "COVID-19", "Cancer Patient", "China", "Clinical", "Control Groups", "Coronavirus", "Databases", "Diagnosis", "Diffusion", "Disease", "Encephalopathies", "Excision", "Fatality rate", "Functional Magnetic Resonance Imaging", "Functional disorder", "Gender", "Goals", "Headache", "Health", "Health system", "Hemorrhage", "Hippocampus (Brain)", "Image", "Image Analysis", "Imaging Techniques", "Infection", "Informatics", "Invaded", "Light", "Link", "Lung", "MRI Scans", "Magnetic Resonance Imaging", "Measurement", "Measures", "Methods", "Middle East Respiratory Syndrome Coronavirus", "Multimodal Imaging", "Nasal cavity", "Nausea", "Nervous system structure", "Neuraxis", "Neurologic", "Neurologic Effect", "Neurologic Symptoms", "Neuropsychology", "Olfactory Nerve", "Outcome", "Pathogenicity", "Pathology", "Pathway Analysis", "Patient Selection", "Patients", "Prospective Studies", "Protocols documentation", "Radiologic Finding", "Recovery", "Reporting", "Resolution", "Respiration", "Respiratory Center", "Respiratory Signs and Symptoms", "Respiratory System", "Respiratory distress", "Rest", "Retrospective Studies", "SARS coronavirus", "Sample Size", "Scanning", "Skull Base Neoplasms", "Smell Perception", "Stroke", "Structure", "Survivors", "Techniques", "Testing", "Thalamic structure", "Time", "Travel", "United States National Institutes of Health", "Vagus nerve structure", "Ventilator", "Virus", "Virus Diseases", "Work", "brain abnormalities", "brain tissue", "brain volume", "cancer diagnosis", "cohort", "contrast enhanced", "cytokine release syndrome", "design", "falls", "graph theory", "improved", "insight", "interest", "magnetic field", "malignant neurologic neoplasms", "mental state", "multimodality", "nervous system disorder", "neuroimaging", "olfactory bulb", "patient population", "patient subsets", "recruit", "respiratory", "response", "targeted imaging", "tool", "tractography", "ventilation" ], "approved": true } }, { "type": "Grant", "id": "10414", "attributes": { "award_id": "1S10OD030381-01A1", "title": "7T Cryogen-Free Preclinical MRI for small animals to study infectious diseases in BSL-3 containment", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 25507, "first_name": "Xiang-Ning", "last_name": "Li", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-20", "end_date": "2023-09-19", "award_amount": 1695141, "principal_investigator": { "id": 21010, "first_name": "Sanjay", "last_name": "Jain", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Infectious diseases are a major threat to humanity, and new tools are needed to study disease pathogenesis and aid the development of novel diagnostics, biomarkers and therapeutics. The alarming rise of highly virulent and multi-drug resistant (MDR) pathogens, their rapid spread, global pandemics such as COVID-19 and continued life-threatening nosocomial infections in hospitals, remain as major challenges to human health. Tomographic molecular imaging enables rapid, noninvasive visualization, localization and monitoring of molecular processes deep within the body and offers several advantages over traditional tools used for the study of infectious diseases. We are requesting a 7T Cryogen-Free preclinical Magnetic Resonance Imaging (MRI) system manufactured by MR Solutions (model 7024) to study infectious diseases in biosafety level-3 (BSL-3) containment at a centralized core facility. Since 2009, the Johns Hopkins Center for Infection and Inflammation Imaging Research (Ci3R) has developed and supported preclinical molecular imaging (PET, SPECT, CT) for infections and inflammatory disorders and established an entirely new user base comprising several NIH- funded infectious diseases investigators within the Johns Hopkins University. While many investigators study Mycobacterium tuberculosis and more recently SARS-CoV-2 – both of which are designated as BSL-3 pathogens with special biosafety needs – Ci3R also supports other researchers that study MDR bacteria (e.g. MRSA) and viral agents such as Zika. Several new approaches for infection imaging have been developed at Ci3R and translated to the clinic. MRI has many advantages over radiopharmaceutical imaging, including high-spatial resolution and contrast. 1H and 19F MR spectroscopic imaging (19F MRSI) and chemical exchange saturation transfer (CEST) contrast would support complementary approaches for molecular imaging of infectious diseases. Therefore, the addition of a high-field preclinical MRI will greatly boost the research efforts related to infectious diseases imaging, while also leveraging the strong MRI expertise within Johns Hopkins University led by NIH-funded investigators. Imaging technologies for infectious diseases are an emerging field of research and overcome several fundamental limitations of current tools in infectious diseases. Therefore, these technologies can have a broad impact on both basic research and patient care. Beyond diagnosis and monitoring infections, these technologies will also provide a uniform cross-species platform for animal studies, allow unique insights into understanding disease pathogenesis and expedite bench-to-bedside translation of new therapeutics. Finally, since MRI is readily available for humans, including high-field 7T systems, validated techniques may become valuable tools for clinical applications in infectious diseases and for enabling precision medicine.", "keywords": [ "2019-nCoV", "Animals", "Basic Science", "COVID-19", "Chemicals", "Clinic", "Communicable Diseases", "Containment", "Core Facility", "Development", "Diagnosis", "Disease", "Emerging Communicable Diseases", "Funding", "Health", "Hospitals", "Human", "Image", "Imaging technology", "Infection", "Inflammation", "Inflammatory", "Life", "Magnetic Resonance Imaging", "Modeling", "Molecular", "Monitor", "Multiple Bacterial Drug Resistance", "Mycobacterium tuberculosis", "Nosocomial Infections", "Pathogenesis", "Patient Care", "Positron-Emission Tomography", "Process", "Radiopharmaceuticals", "Research", "Research Personnel", "Resolution", "System", "Techniques", "Technology", "Therapeutic", "Translating", "United States National Institutes of Health", "Universities", "Viral", "Virulent", "Visualization", "ZIKA", "base", "bench-to-bedside translation", "clinical application", "diagnostic biomarker", "imaging system", "insight", "methicillin resistant Staphylococcus aureus", "molecular imaging", "multi-drug resistant pathogen", "novel diagnostics", "novel strategies", "novel therapeutics", "pandemic disease", "pathogen", "pre-clinical", "precision medicine", "single photon emission computed tomography", "spectroscopic imaging", "tomography", "tool" ], "approved": true } }, { "type": "Grant", "id": "11442", "attributes": { "award_id": "1R44AI176894-01", "title": "7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6908, "first_name": "JENNIFER L.", "last_name": "Gordon", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-04-26", "end_date": "2025-03-31", "award_amount": 928224, "principal_investigator": { "id": 27504, "first_name": "Siddhartha", "last_name": "De", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 7827, "first_name": "Michael", "last_name": "Schotsaert", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, { "id": 12235, "first_name": "Upendra", "last_name": "Marathi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 27505, "first_name": "William", "last_name": "Schary", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1184, "ror": "", "name": "7 HILLS PHARMA, LLC", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "Americans aged ≥65 years accounted for 57% and 75% of all influenza-related hospitalizations and deaths, respectively, in the 2019-20 season, despite a vaccination rate of ~68%. Flu vaccine effectiveness is lower in the elderly than in younger adults, requiring either a high-dose (Fluzone® HD) or an adjuvanted (FluAd®) vaccine. Antigen mismatch in vaccine vs. circulating strains results in insufficient protection, and poor responses in the elderly remain major public health concerns. Cell-mediated immunity may correlate better than humoral immunity for vaccine protection in the elderly. Adjuvants used to enhance vaccine efficacy, such as MPLA, CpG and alum, trigger either innate or antibody responses, but not a T cell response. While existing adjuvants or increased antigen load may partially improve seroconversion, overall vaccine effectiveness and T cell responses may be suboptimal in at-risk populations. New adjuvants are needed that induce robust T cell responses for pathogen clearance. A key factor for suboptimal vaccine effectiveness in the elderly is immunosenescence, a gradual age-related immune decline. Prolonged cell adhesion mediated by integrins α4β1 and αLβ2 and their cognate ligands, VCAM-1 and ICAM-1, is essential for effective antigen presentation and T cell priming at the immune synapse between antigen presenting cells (APCs) and naïve T cells, as well as for T cell memory and effector functions. Deficient APC-T cell adhesion attenuates T cell activation and memory. Age-related defects in ICAM-1 induction on activated dendritic cells may decrease T cell priming, resulting in suboptimal vaccine effectiveness in the elderly. 7HP349 is a first-in-concept, oral, small-molecule, allosteric α4β1/αLβ2 activator that may promote APC-T cell adhesion, and improve T helper function and the effectiveness of geriatric influenza vaccination. In mice, 7HP349 significantly improved the effectiveness of influenza, Chagas disease, SARS-CoV- 2 and tuberculosis vaccines, not only via humoral responses but also cell-mediated immunity, which differentiates it from current or emerging competition. A first-in-human Phase I clinical study to evaluate the safety, tolerability and PK of 7HP349 in healthy male subjects was completed in 4Q 2021. 7HP349 was shown to be safe and orally bioavailable, with no treatment-related serious adverse events. Additionally, the optimal pharmacokinetic dose was identified. In this application, we propose to evaluate 7HP349 as an oral adjuvant to influenza vaccination in aging mice with pre-existing immunity, that would be representative of vaccination in the elderly. Additionally, to activate a supplemental IND for geriatric influenza, we plan to complete additional required Chemistry, Manufacturing and Control activities that will include development of a 100 mg strength to enable once daily, one pill dosing to improve patient compliance, and manufacture of cGMP 7HP349 Drug Product to support the IND and build inventory for a future Phase I/IIa clinical study in elderly subjects to assess the safety of 7HP349 and to evaluate its immunogenicity in combination with Fluzone® HD, which will also lay the foundation for its potential use in enhancing the effectiveness of other infectious disease vaccines in vulnerable sub-populations.", "keywords": [ "2019-nCoV", "Adjuvant", "Aging", "Agreement", "American", "Animal Model", "Antibody Response", "Antigen Presentation", "Antigen-Presenting Cells", "Antigens", "Attenuated", "B-Lymphocytes", "Biological Assay", "Biological Availability", "Cell Adhesion", "Cellular Immunity", "Cessation of life", "Chagas Disease", "Chemistry", "Clinical", "Clinical Data", "Clinical Research", "Clinical Trials", "Communicable Diseases", "Control Groups", "Cross Reactions", "Cyclic GMP", "Defect", "Dendritic Cells", "Development", "Disease", "Dosage Forms", "Dose", "Drug Kinetics", "Effectiveness", "Elderly", "Enzyme-Linked Immunosorbent Assay", "Equipment and supply inventories", "Exposure to", "Flow Cytometry", "Fluzone", "Formulation", "Foundations", "Future", "Guidelines", "Hemagglutinin", "Hospitalization", "Human", "Humoral Immunities", "Immune", "Immune response", "Immune system", "Immunity", "Immunoglobulin A", "Immunoglobulin G", "Immunoglobulin M", "Individual", "Infection", "Influenza", "Influenza A Virus H1N1 Subtype", "Influenza A Virus H5N1 Subtype", "Influenza vaccination", "Integrin alpha4beta1", "Integrin-mediated Cell Adhesion Pathway", "Integrins", "Intercellular adhesion molecule 1", "Life", "Ligands", "MF59", "Measures", "Memory", "Morbidity - disease rate", "Mucous Membrane", "Mus", "Neuraminidase", "New Caledonia", "Oral", "Pharmaceutical Preparations", "Phase", "Play", "Populations at Risk", "Public Health", "Recommendation", "Risk", "Role", "Safety", "Schedule", "Seasons", "Serious Adverse Event", "Serum", "Shapes", "Speed", "Surrogate Markers", "T cell response", "T memory cell", "T-Cell Activation", "T-Lymphocyte", "Testing", "Time", "Tuberculosis Vaccines", "Vaccinated", "Vaccination", "Vaccines", "Vascular Cell Adhesion Molecule-1", "Viral", "Viral Antigens", "Virus", "Work", "adaptive immunity", "age related", "aged", "aluminum sulfate", "cell motility", "compliance behavior", "cross reactivity", "enzyme linked immunospot assay", "first-in-human", "human old age (65+)", "immunogenicity", "immunological synapse", "immunosenescence", "improved", "influenza infection", "influenza virus strain", "influenza virus vaccine", "influenzavirus", "male", "meetings", "mortality", "mouse model", "pandemic disease", "pathogen", "pill", "pre-clinical", "preclinical study", "programs", "residence", "response", "safety assessment", "safety testing", "seroconversion", "small molecule", "va" ], "approved": true } }, { "type": "Grant", "id": "9645", "attributes": { "award_id": "2133323", "title": "79th Device Research Conference. To Be Held Virtually June 20-23, 2021.", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Engineering (ENG)", "EPMD-ElectrnPhoton&MagnDevices" ], "program_reference_codes": [], "program_officials": [ { "id": 1186, "first_name": "Lawrence", "last_name": "Goldberg", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-06-01", "end_date": "2022-05-31", "award_amount": 10000, "principal_investigator": { "id": 6447, "first_name": "Shaloo", "last_name": "Rakheja", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 25464, "first_name": "J. Ardie Butch", "last_name": "Dillen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 792, "ror": "https://ror.org/04jg8an89", "name": "Materials Research Society", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Non-Technical Description: This project will use NSF support to increase student participation and enhance technical training at the 79th Device Research Conference (DRC), which brings together researchers from around the world to share their latest findings in the areas of electronic, opto-electronic, and quantum-based semiconductor devices. The 2021 DRC will be held virtually from June 20 to 23, 2021, and all participants will join remotely. The DRC offers unique training and networking opportunities particularly to its student and young investigator attendees, helping them advance their careers in materials science, semiconductor technology, and device engineering. The DRC is committed to fostering greater diversity and equity for all attendees and at all levels. By stimulating an open and frank discussion of recent breakthroughs and advances in electronic and photonic devices, the DRC will remove barriers for underrepresented minority groups and also support the NSF’s Diversity Mission related to “preparing a diverse, globally engaged science, technology, engineering and mathematics workforce.” \n\nTechnical Description: The 2021 DRC will feature three plenary talks from world-renowned researchers in heterogeneous integration, III-nitride technology, and van der Waals materials. The conference will include presentations on devices for IoT, spintronic devices, memory devices, RF and terahertz devices, thin-film devices, and heterogeneous integration. In addition to plenary talks and oral presentations, the 2021 DRC will offer a half-day technical shortcourse in the area of “Quantum Computing Devices and Materials” taught by prominent experts from academia and industry. The 2021 DRC will also feature a rump session titled “Ferroelectric-based devices: What is the future?” to engage the audience in a vigorous and open discussion on the future of ferroelectric devices. The conference program, including the rump session and the shortcourse, will greatly enhance the usefulness of the conference to all attendees. The information will be disseminated through online video presentations, downloadable posters and the conference proceedings.\n\nThis award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "4101", "attributes": { "award_id": "1632758", "title": "74th Device Research Conference 2016, June 19 to 22, 2016, University of Delaware, Newark,DE", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Unknown", "EPMD-ElectrnPhoton&MagnDevices" ], "program_reference_codes": [], "program_officials": [], "start_date": "2016-06-15", "end_date": "2017-05-31", "award_amount": 10000, "principal_investigator": { "id": 13773, "first_name": "Aaron", "last_name": "Franklin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 792, "ror": "https://ror.org/04jg8an89", "name": "Materials Research Society", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 13772, "first_name": "J. Ardie Butch", "last_name": "Dillen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 792, "ror": "https://ror.org/04jg8an89", "name": "Materials Research Society", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "The 74th Device Research Conference (DRC) has a University setting and will take place at the University of Delaware, Newark, DE from June 19 to 22, 2016. Topics to be addressed include biological devices, emerging Electronic device materials (graphene, MoS2), devices for energy scavenging power, memory, nanoscale applications, including Terahertz and spin-based approaches. The Conference seeks financial support to underrepresented minorities as invited speakers as well as students, It has a strong tradition of student involvement, with strong student attendance to its short courses, poster session and oral presentations. The DRC also has a tradition of offering discounted student registration fees, not only for general attendance but also for its short courses, in order to encourage student participation and attendance from additional students who are not presenting an abstract. Support will allow offering 50% discount for student registration to the general conference and the day-long short course \"Device Fundamentals You Were Never Taught: Interpreting Your Device Data\" held just prior to the beginning of the conference.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8868", "attributes": { "award_id": "1R13HG012147-01", "title": "6th International Conference: Genomic Medicine Implementation in Low Resource Settings", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Human Genome Research Institute (NHGRI)" ], "program_reference_codes": [], "program_officials": [ { "id": 24686, "first_name": "Christine Q", "last_name": "Chang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-21", "end_date": "2022-02-28", "award_amount": 36350, "principal_investigator": { "id": 24687, "first_name": "GABRIELA", "last_name": "REPETTO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1771, "ror": "", "name": "GLOBAL GENOMIC MEDICINE COLLABORATIVE", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1771, "ror": "", "name": "GLOBAL GENOMIC MEDICINE COLLABORATIVE", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "The Global Genomics Medicine Collaborative (G2MC) requests support for its 6th International Conference: Genomic Medicine Implementation in Low Resource Settings, organized by Drs. Geoffrey S. Ginsburg, Gabriela Repetto and Bruce Korf. The event will be held on September 29 - October 1, 2021 in Santiago, Chile. G2MC is a not-for-profit organization based in the United States with the goal of bringing together the global community to enable the implementation of genomic medicine to improve individual and population health. Many nations are investing in large-scale national genomic medicine programs. To maximize the value of this investment, we propose this gathering as a means to ‘de-silo’ these efforts and bring them together to inform implementation into healthcare delivery systems across diverse populations, demographics, and economies. To optimize the probability of success for implementing genomics into health care is it necessary to bring the leaders at the forefront of genomic medicine together in a forum conducive to impactful conversations and dialogues. While genomic medicine offers major opportunities for prevention, diagnosis, and treatment of disease, there is a significant risk that it will exacerbate disparities in access to healthcare. This is true in high-income countries such as the United States but is even more a concern in low resource settings (LRS). G2MC has selected the event location to enable engagement with regional attendees from Latin America, a traditionally underrepresented group in genomic medicine. The conference agenda will facilitate a deeper understanding of best practices from subject matter experts that can be applied to genomic medicine and advancement of G2MC’s implementation Flagship Projects. The conference will also provide a unique opportunity to mentor Young Investigators (YIs) from lower- and middle-resourced countries in Latin America and beyond by established G2MC investigators and high-profile speakers from around the world with expertise in genomic medicine. Given the current COVID-19 pandemic, this meeting is planned as a hybrid in-person and virtual event. G2MC will encourage YIs to attend in person, if possible, so as to increase their visibility, and highlight their achievements. An explicit goal of this meeting is to advance the careers of YIs through their interaction with G2MC members/investigators through mentorship, networking, dissemination of their research. YIs will also engage with G2MC Flagship Projects and working groups, leading to further opportunities for collaboration. The 6th International G2MC Conference is unique in emphasizing implementation through outreach with YIs as well as speaker and attendee representation from LRS. The agenda objectives emphasize solutions to implementation roadblocks by engaging with a truly global group of presenters and attendees to enable the successful implementation of genomic medicine around the world.", "keywords": [ "Academia", "Achievement", "Advocate", "Affect", "COVID-19 pandemic", "Caring", "Chile", "Clinical Trials", "Collaborations", "Communities", "Country", "Development", "Diagnosis", "Discipline", "Disease", "Education", "Elements", "Epidemiologist", "Event", "Family", "Fostering", "Future", "Genomic medicine", "Genomics", "Geography", "Goals", "Government", "Health", "Health Personnel", "Health system", "Healthcare", "Human", "Hybrids", "Income", "Individual", "Industry", "International", "Investments", "Latin America", "Lead", "Leadership", "Location", "Malignant Neoplasms", "Mentors", "Mentorship", "Outcome", "Participant", "Patients", "Persons", "Pharmacogenomics", "Physicians", "Play", "Policies", "Policy Maker", "Population Heterogeneity", "Prevention", "Privatization", "Probability", "Rare Diseases", "Recording of previous events", "Research", "Research Personnel", "Resources", "Risk", "Role", "Scientist", "System", "Time", "Training", "Travel", "Uncertainty", "Underrepresented Populations", "United States", "Work", "base", "career", "career development", "clinical application", "cost", "demographics", "evidence based guidelines", "health care availability", "health care delivery", "implementation science", "improved", "meetings", "member", "outreach", "patient population", "population health", "posters", "programs", "success", "symposium", "therapeutic development", "virtual", "working group" ], "approved": true } }, { "type": "Grant", "id": "2567", "attributes": { "award_id": "2010561", "title": "6th International Conference of Quantitative Genetics (ICQG6)", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Biological Sciences (BIO)", "Integrtv Ecological Physiology" ], "program_reference_codes": [], "program_officials": [ { "id": 7394, "first_name": "Theodore", "last_name": "Morgan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-15", "end_date": "2021-08-31", "award_amount": 47280, "principal_investigator": { "id": 7395, "first_name": "Bruce", "last_name": "Weir", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Sixth International Conference of Quantitative Genetics (ICQG6) will be held in Brisbane, Australia, June 2021. Quantitative genetics is concerned with traits for which variation between individuals is controlled in part by DNA differences between individuals. These traits include those that are affected by environmental factors and change during evolution and that affect human health or economic traits in domesticated plants and animals. The hereditary component for these traits is often complex and requires sophisticated mathematical and statistical analyses to relate observed trait values to genetic profiles. Quantitative geneticists are now addressing very large genetic datasets made possible by advances in molecular biology, with human genetic studies now capable of revealing information for a billion separate genetic elements, and the scale of data is also large for plants and animals. The ICQG6 will bring over 500 scientists and students together to survey the current state of the field and to consider future activities.\n\nThe Sixth International Conference of Quantitative Genetics (ICQG6) to be held in Brisbane, Australia, June 2021. Important health problems will are addressed in this application by an emphasis on the genetic determinants of human disease. Studies of disease rest heavily on sound statistical methodology. Many new statistical techniques that address complex traits and the integration of genotype, gene expression and clinical trait data will be covered in the Conference. Advances in human health often follow the studies made on model organisms to be described at the ICQG6. Use of model organisms requires an understanding of the shared evolutionary history of man and other organisms, and some speakers will address the evolution of quantitative traits. Quantitative genetic methodology, especially techniques for mapping quantitative trait loci (QTL), is often developed for plant and animal populations where controlled crosses can be made. Advances in plant and animal breeding also lead to improved human health by increasing the quality and quantity of food. The technological advances of the last decade have meant that quantitative genetic studies are being conducted at an unprecedented scale. Moreover, there are also studies on the quantitative genetics of omics traits, including at the single-cell level. Many conference attendees develop new methods that are applicable across a range of species and traits. In particular, progress in human genetics has been made with methodology developed in livestock genetics. Dialog between methodologists across species has been found to provide new ideas, new directions and new ways of thinking.\n\nThis award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1405, "pages": 1424, "count": 14236 } } }